NVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Novo Nordisk is not a strong buy at this time for a beginner investor with a long-term strategy. While the company has a solid financial performance and hedge funds are increasing their positions, the technical indicators are bearish, and the stock is under pressure due to weaker guidance and competition in the weight-loss drug market. The options data indicates a neutral to slightly bearish sentiment, and there are no strong proprietary trading signals to support an immediate buy decision. A hold position is recommended until clearer positive catalysts emerge.
The technical indicators are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 37.833, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 51.15, with key support at 44.782 and resistance at 57.518.
Hedge funds are increasing their positions significantly (112.57% increase in buying). The company is expanding its manufacturing capacity for Wegovy, which could enhance its global market presence. The launch of Wegovy in vials may help compete with Eli Lilly.
The company has downgraded its sales outlook for 2026, and analysts have lowered price targets due to weaker guidance. Competitors like Eli Lilly and Viking Therapeutics are advancing in the weight-loss drug market, posing significant competition. The MACD and moving averages indicate a bearish trend.
In Q4 2025, revenue increased by 0.69% YoY, net income rose by 3.84% YoY, and EPS grew by 3.30% YoY. However, gross margin dropped by -4.65% YoY to 80.86, indicating some pressure on profitability.
Analysts have mixed views. Jefferies upgraded the stock to Hold, citing better-reflected outlooks, while other firms like BMO, BofA, and Citi have lowered price targets due to weaker guidance. Goldman Sachs remains optimistic with a Buy rating, citing the Wegovy pill launch as a potential near-term driver.
